DENTSPLY SIRONA Inc.
DENTSPLY SIRONA Inc. is a globally recognized key player in the dental care market, distinguished for its comprehensive portfolio of professional dental products and technologies. The company is actively involved in the Periodontal Disease Treatment market by providing a variety of innovative dental solutions and equipment essential for the effective management of periodontal diseases. Their product line is crucial for dental professionals, offering solutions for periodontal scaling, root planing, and long-term maintenance therapy, which are the foundational non-surgical treatments for gum disease. DENTSPLY SIRONA’s commitment to advancing treatment options is exemplified by recent product introductions, such as the Perio-Shield™ Plus Gel, a topical chlorhexidine gel designed for plaque control and gum support. The company supports dental professionals globally through its robust distribution network, ensuring practitioners have access to the latest technologies to enhance patient outcomes and streamline complex periodontal care workflows, reinforcing its vital role in the oral health landscape.
Latest Market Research Report on Periodontal Disease Treatment Download PDF Brochure Now
Straumann Group (INSTITUT STRAUMANN AG)
The Straumann Group (INSTITUT STRAUMANN AG) stands as a global leader in dental implantology and restorative dentistry, leveraging its expertise to significantly contribute to the Periodontal Disease Treatment market. The company’s involvement extends beyond basic restoration, focusing on advanced solutions for periodontal regeneration and healing in patients with advanced gum disease. Straumann is a prominent provider of regenerative products and specialized biomaterials. This portfolio includes critical products such as bone grafts and membranes, which are essential components used by periodontists in surgical procedures to restore and regenerate lost bone and gum tissue caused by periodontitis. These advanced materials promote the reconstruction of the supporting structures of the teeth, which is vital for saving teeth and preparing sites for successful dental implants. By offering high-quality, scientifically backed regenerative solutions, the Straumann Group maintains its position at the forefront of enabling complex, successful periodontal surgeries and improving long-term oral health for patients worldwide.
OraPharma
OraPharma is a key pharmaceutical company focused on innovative therapeutic solutions for the dental health market, particularly renowned for its targeted approach to Periodontal Disease Treatment. The company is best known as the manufacturer of ARESTIN (minocycline hydrochloride) microspheres, a landmark product in the nonsurgical treatment of periodontitis. ARESTIN is the only FDA-approved, locally applied antibiotic specifically designed for use in conjunction with scaling and root planing (SRP). This site-specific delivery system targets the infection deep within the periodontal pockets, helping to reduce pocket depth and disrupt the disease process effectively. In a demonstration of continuous innovation, OraPharma recently received FDA clearance for Evomin, a novel non-antibiotic, topical option for gingivitis management, broadening its therapeutic offerings. Through its specialty products, OraPharma plays a crucial role in providing periodontists and dentists with convenient, targeted, and powerful tools to manage and treat gum disease, thus improving patient compliance and clinical outcomes.
Amyndas Pharmaceuticals
Amyndas Pharmaceuticals is an emerging biopharmaceutical company focused on developing novel therapeutics for inflammatory and complement-mediated diseases, with a strategic focus on Chronic Periodontitis Treatment. The company is developing AMY-101, which is a novel oral peptide. This investigational therapy is designed to address the underlying inflammatory components of gum disease, offering a different approach compared to traditional antibiotics or mechanical debridement. AMY-101 has shown promising results in Phase 2b clinical trials for treating both gingivitis and periodontitis, demonstrating its potential to be a significant addition to the therapeutic landscape for periodontal disease. By targeting key biological pathways involved in inflammation and tissue destruction, Amyndas is working to provide a systemic, disease-modifying treatment option. The progress of AMY-101 through the clinical pipeline highlights Amyndas Pharmaceuticals’ commitment to advancing oral health through biotechnology and suggests its future role as a key player providing next-generation treatments for chronic gum disease.
Perio Protect
Perio Protect specializes in providing minimally invasive, highly effective home-care solutions for the management and treatment of gum disease, distinguishing itself in the Periodontal Disease Treatment market. The company’s flagship offering is the patented, prescription Perio Tray™ therapy. This system involves a custom-fabricated, deep-delivery tray that a patient uses at home to apply prescribed medication gels, typically containing hydrogen peroxide, deep below the gum line. The tray is engineered to deliver the medication precisely to the infected areas, helping to disrupt the bacterial colonies (biofilm) that cause periodontitis and gingivitis. This non-invasive approach is designed to be used in conjunction with professional treatments like scaling and root planing, helping to reduce inflammation, pocket depths, and bleeding gums. Perio Protect’s innovative technology empowers patients to take a more active role in their daily gum health maintenance, offering a key complementary strategy that can lead to significant and sustainable improvements in oral health.
Latest Market Research Report on Periodontal Disease Treatment Download PDF Brochure Now